A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results

被引：125

作者：

Zolopa, Andrew ^{[1
]}

Sax, Paul E. ^{[2
]}

DeJesus, Edwin ^{[3
]}

Mills, Anthony ^{[4
]}

Cohen, Calvin ^{[5
]}

Wohl, David ^{[6
]}

Gallant, Joel E. ^{[7
]}

Liu, Hui C. ^{[8
]}

Plummer, Andrew ^{[8
]}

White, Kirsten L. ^{[8
]}

Cheng, Andrew K. ^{[8
]}

Rhee, Martin S. ^{[8
]}

Szwarcberg, Javier ^{[8
]}

机构：

[1] Stanford Univ, Div Infect Dis & Geog Med, Palo Alto, CA 94304 USA

[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA

[3] Orlando Immunol Ctr, Orlando, FL USA

[4] Anthony Mills MD Inc, Los Angeles, CA USA

[5] Community Res Initiat New England, Boston, MA USA

[6] Univ N Carolina, Div Infect Dis, Chapel Hill, NC USA

[7] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA

[8] Gilead Sci Inc, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2013年 / 63卷 / 01期

关键词：

HIV; stribild; cobicistat; phase 3 randomized trial; efficacy; safety; CO-FORMULATED ELVITEGRAVIR; NON-INFERIORITY TRIAL; TREATMENT-NAIVE; EFAVIRENZ; LOPINAVIR/RITONAVIR; COBICISTAT; TENOFOVIR; RITONAVIR; EFFICACY; PHASE-3;

D O I：

10.1097/QAI.0b013e318289545c

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference + 3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA <50 copies/mL) was maintained at week 96 (84% vs 82%, difference +2.7%, 95% CI: -2.9% to 8.3%). Discontinuation due to adverse events was low (5% vs 7%). Median changes in serum creatinine (mg/dL) at week 96 were similar to week 48. These results support the durable efficacy and long-term safety of EVG/COBI/FTC/TDF.

引用

页码：96 / 100

页数：5

共 50 条

[1] A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
Wohl, David
Oka, Shinichi
Clumeck, Nathan
Clarke, Amanda
Brinson, Cynthia
Stephens, Jeffrey
Tashima, Karen
Arribas, Jose R.
Rashbaum, Bruce
Cheret, Antoine
Brunetta, Jason
Mussini, Cristina
Tebas, Pablo
Sax, Paul E.
Cheng, Andrew
Zhong, Lijie
Callebaut, Christian
Das, Moupali
Fordyce, Marshall
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (01) : 58 - 64
[2] Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
Cohen, Calvin
Elion, Richard
Ruane, Peter
Shamblaw, David
DeJesus, Edwin
Rashbaum, Bruce
Chuck, Steven L.
Yale, Kitty
Liu, Hui C.
Warren, David R.
Ramanathan, Srinivasan
Kearney, Brian P.
[J]. AIDS, 2011, 25 (06) : F7 - F12
[3] A randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results
Clarke, A.
Wohl, D.
Oka, S.
Clumeck, N.
Brinson, C.
Tashima, K.
Arribas, J.
Cheret, A.
Brunetta, J.
Sax, P.
Zhong, L.
Das, M.
Fordyce, M.
Elliott, C.
[J]. HIV MEDICINE, 2016, 17 : 14 - 14
[4] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment
Olin, Jacqueline L.
Spooner, Linda M.
Klibanov, Olga M.
[J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) : 1671 - 1677
[5] Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results
Arribas, Jose R.
Thompson, Melanie
Sax, Paul E.
Haas, Bernhard
McDonald, Cheryl
Wohl, David A.
DeJesus, Edwin
Clarke, Amanda E.
Guo, Susan
Wang, Hui
Callebaut, Christian
Plummer, Andrew
Cheng, Andrew
Das, Moupali
McCallister, Scott
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) : 211 - 218
[6] Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Venter, Willem D. F.
Sokhela, Simiso
Simmons, Bryony
Moorhouse, Michelle
Fairlie, Lee
Mashabane, Nkuli
Serenata, Celicia
Akpomiemie, Godspower
Masenya, Masebole
Qavi, Ambar
Chandiwana, Nomathemba
McCann, Kaitlyn
Norris, Shane
Chersich, Matthew
Maartens, Gary
Lalla-Edward, Samanta
Vos, Alinda
Clayden, Polly
Abrams, Elaine
Arulappan, Natasha
Hill, Andrew
[J]. LANCET HIV, 2020, 7 (10): : E666 - E676
[7] Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Sax, Paul E.
Wohl, David
Yin, Michael T.
Post, Frank
DeJesus, Edwin
Saag, Michael
Pozniak, Anton
Thompson, Melanie
Podzamczer, Daniel
Molina, Jean Michel
Oka, Shinichi
Koenig, Ellen
Trottier, Benoit
Andrade-Villanueva, Jaime
Crofoot, Gordon
Custodio, Joseph M.
Plummer, Andrew
Zhong, Lijie
Cao, Huyen
Martin, Hal
Callebaut, Christian
Cheng, Andrew K.
Fordyce, Marshall W.
McCallister, Scott
[J]. LANCET, 2015, 385 (9987): : 2606 - 2615
[8] Stribild® (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate): A New Paradigm for HIV-1 Treatment
Manzardo, Christian
Gatell, Jose M.
[J]. AIDS REVIEWS, 2014, 16 (01) : 35 - 42
[9] Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
Nozza, Silvia
Poli, Andrea
Ripa, Marco
Galli, Laura
Chiappetta, Stefania
Spagnuolo, Vincenzo
Rovelli, Cristina
Lazzarin, Adriano
Castagna, Antonella
Tambussi, Giuseppe
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (02) : 632 - 633
[10] Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
Ramanathan, Srini
Custodio, Joseph M.
Wei, Xuelian
Wang, Hui
Fordyce, Marshall
Dave, Ami
Ling, Kah Hiing J.
Szwarcberg, Javier
Kearney, Brian P.
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (03) : 281 - 288

← 1 2 3 4 5 →